{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T04:14:36Z","timestamp":1783138476885,"version":"3.54.6"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ygyno.2025.06.014","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T18:43:29Z","timestamp":1751395409000},"page":"96-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["A phase 2 trial of niraparib plus bevacizumab maintenance therapy following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: final analysis and overall survival results from OVARIO"],"prefix":"10.1016","volume":"199","author":[{"given":"Melissa M.","family":"Hardesty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C.","family":"Krivak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail S.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn L.","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy","family":"Belotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelby","family":"Gorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Compton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aine","family":"Clements","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi J.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gottfried E.","family":"Konecny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra L.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2025.06.014_bb0005","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2025.06.014_bb0010","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2025.06.014_bb0015","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2025.06.014_bb0020","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2025.06.014_bb0025","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Gonzalez-Martin","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2025.06.014_bb0030","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1200\/GO.21.00085","article-title":"Assessment of adult women with ovarian masses and treatment of epithelial ovarian cancer: ASCO resource-stratified guideline","volume":"7","author":"Vanderpuye","year":"2021","journal-title":"JCO Glob. Oncol."},{"key":"10.1016\/j.ygyno.2025.06.014_bb0035","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1200\/JCO.22.01934","article-title":"PARP inhibitors in the Management of Ovarian Cancer Guideline Expert Panel, poly(ADP-ribose) polymerase inhibitors in the management of ovarian cancer: ASCO Guideline Rapid Recommendation Update","volume":"40","author":"Tew","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.06.014_bb0040","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ygyno.2022.05.020","article-title":"OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab","volume":"166","author":"Hardesty","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.06.014_bb0045","author":"Functional Assessment of Cancer Therapy Ovarian Cancer Symptom Index - 8 Item Version 2023"},{"key":"10.1016\/j.ygyno.2025.06.014_bb0050","author":"FACT\/NCCN Ovarian Symptom Index (FOSI) Scoring Guidelines (Version 4) 2023"},{"key":"10.1016\/j.ygyno.2025.06.014_bb0055","doi-asserted-by":"crossref","first-page":"16021","DOI":"10.1200\/jco.2007.25.18_suppl.16021","article-title":"Validation of the functional assessment of Cancer therapy-ovarian (FACT-O) symptom index (FOSI) in a phase II clinical trial of pertuzumab in patients with advanced ovarian cancer","volume":"25","author":"Beaumont","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.06.014_bb0060","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ygyno.2024.01.021","article-title":"Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: results from the phase 3 randomized PRIMA\/ENGOT-OV26\/GOG-3012 trial","volume":"184","author":"Pothuri","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.06.014_bb0065","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2025.06.014_bb0070","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.annonc.2024.08.2241","article-title":"Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial","volume":"35","author":"Monk","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2025.06.014_bb0075","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2025.06.014_bb0080","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","article-title":"Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Ray-Coquard","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2025.06.014_bb0085","article-title":"Optimal primary surgical treatment for advanced epithelial ovarian cancer","volume":"2011","author":"Elattar","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ygyno.2025.06.014_bb0090","article-title":"The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis","volume":"9","author":"Sun","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2025.06.014_bb0095","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ygyno.2022.04.012","article-title":"Efficacy of niraparib by time of surgery and postoperative residual disease status: a post hoc analysis of patients in the PRIMA\/ENGOT-OV26\/GOG-3012 study","volume":"166","author":"O\u2019Cearbhaill","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.06.014_bb0100","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2025.06.014_bb0105","article-title":"Association of multiple high-risk factors on observed outcomes in real-world patients with advanced ovarian cancer treated with first-line therapy","volume":"7","author":"Chase","year":"2023","journal-title":"JCO Clin. Cancer Inform."},{"key":"10.1016\/j.ygyno.2025.06.014_bb0110","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1002\/cncr.29082","article-title":"Intermediate clinical endpoints: a bridge between progression-free survival and overall survival in ovarian cancer trials","volume":"121","author":"Matulonis","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2025.06.014_bb0115","first-page":"1121","article-title":"Clinical endpoints in oncology - a primer","volume":"11","author":"Delgado","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ygyno.2025.06.014_bb0120","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1136\/ijgc-2023-004944","article-title":"AGO-OVAR 28\/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trial","volume":"33","author":"Heitz","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2025.06.014_bb0125","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2217\/fon-2023-0167","article-title":"NIRVANA-1: maintenance therapy with niraparib versus niraparib-bevacizumab in patients with advanced ovarian cancer","volume":"19","author":"Sghaier","year":"2023","journal-title":"Future Oncol."},{"key":"10.1016\/j.ygyno.2025.06.014_bb0130","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ygyno.2021.01.028","article-title":"The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: a systematic review and meta-analysis","volume":"161","author":"Liu","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2025.06.014_bb0135","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1136\/ijgc-2022-004079","article-title":"Safety and management of niraparib monotherapy in ovarian cancer clinical trials","volume":"33","author":"Monk","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2025.06.014_bb0140","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3390\/curroncol29010029","article-title":"Safety profile of niraparib as maintenance therapy for ovarian cancer: a systematic review and meta-analysis","volume":"29","author":"Pagkali","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ygyno.2025.06.014_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114157","article-title":"Tolerability of the niraparib individualized starting dose in the PRIMA\/ENGOT-OV26\/GOG-3012 trial of niraparib first-line maintenance therapy","volume":"208","author":"Vulsteke","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2025.06.014_bb0150","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ejca.2022.07.022","article-title":"Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1\/ENGOT-ov25 trial","volume":"174","author":"Gonzalez-Martin","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2025.06.014_bb0155","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","article-title":"Exploring and comparing adverse events between PARP inhibitors","volume":"20","author":"LaFargue","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2025.06.014_bb0160","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJM199902043400504","article-title":"Risk of leukemia after platinum-based chemotherapy for ovarian cancer","volume":"340","author":"Travis","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2025.06.014_bb0165","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.22.01549","article-title":"Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial","volume":"41","author":"DiSilvestro","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.06.014_bb0170","first-page":"7","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2025.06.014_bb0175","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2025.06.014_bb0180","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825008819?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825008819?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T08:19:46Z","timestamp":1777018786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825825008819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":36,"alternative-id":["S0090825825008819"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.06.014","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 2 trial of niraparib plus bevacizumab maintenance therapy following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: final analysis and overall survival results from OVARIO","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 GSK. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}